Therapeutic Immunology
1994, **1**, 349–351

Index

Author Index

Abbs IC, Clark M, Waldmann H, Chatenoud L, Koffman CG, Sacks SH. Sparing of first dose effect of monovalent anti-CD3 antibody used in allograft rejection is associated with diminished release of pro-inflammatory cytokines, 325
Acres B, Dott K, Stefani L, Kieny M-P. Directed cytokine expression in tumour cells *in vivo* using recombinant vaccinia virus, 17
Akiyama S *see* Uchida S
Anderson TD *see* Gately MK
Arnon R, Teitelbaum D. Immunospecific drug design – prospects for treatment of autoimmune diseases, 65

Bajorath J *see* Hayden MS
Bast EJEG *see* Haagen I-A
Bilge A, Howell-Clark J, Ramakrishnan S, Press OW. Degradation of ricin A chain by endosomal and lysosomal enzymes – the protective role of ricin B chain, 197
Blum S, Milesi R, Tratkiewicz J, Olive D, Gallati H, Cerottini J-C, von Fliedner V. Rapid induction of cytolytic T cells via CD28 stimulation for cellular immunotherapy, 143
Boden B *see* Hall H
Brady WA *see* Hayden MS
Brill AB *see* Matsushita T
Brown CT *see* Przepiorka D
Brunda MJ *see* Gately MK
Burgess J *see* Sutton VR
Burrus-Fischer B *see* Chisholm PL

Cerottini J-C *see* Blum S
Champlin RE *see* Przepiorka D
Chatenoud L *see* Abbs IC
Chisholm PL, Williams CA, Jones WE, Majeau GR, Oleson FB, Burrus-Fischer B, Meier W, Hochman PS. The effects of an immunomodulatory LFA3-IgG_1 fusion protein on non-human primates, 205
Clark M *see* Abbs IC

Delaney CP, Thomson AW, Demetris AJ, Starzl TE. Xenobiotics, chimerism and the induction of tolerance following organ transplantation, 153
Delichatsios H *see* Matsushita T
Demetris AJ *see* Delaney CP
Dietrich G *see* Hurez V
Dott K *see* Acres B
Dower SK, Fanslow W, Jacobs C, Waugh S, Sims JE, Widmer MB. Interleukin-I antagonists, 113

Evan IG. Better dead than red, 343

Fanslow W *see* Dower SK
Fell HP *see* Hayden MS
von Fliedner V *see* Blum S
Fidelus RK *see* Perrin PJ
Fujikura Y *see* Tsuchida M
Fujiwara M *see* Uchida S
Fukumoto T *see* Tsuchida M

Gadina M, Newton DL, Rybak SM, Wu Y-N, Youle RJ. Humanized immunotoxins, 59
Gallati H *see* Blum S
de Gast GC *see* Haagen I-A
Gately MK, Gubler U, Brunda MJ, Nadeau RR, Anderson TD, Lipman JM, Sarmiento U. Interleukin-12: a cytokine with therapeutic potential in oncology and infectious diseases, 187
Gayle MA *see* Hayden MS
Geerars AJG *see* Haagen I-A
Gilliland LK *see* Hayden MS
Gilsson WC *see* Gridley DS
Gorman SD *see* Greenwood J
Greene MI *see* Peterson NC
Greenwood J, Gorman SD, Routledge EG, Lloyd IS, Waldmann H. Engineering multiple-domain forms of the therapeutic antibody CAMPATH-IH: effects on complement lysis, 247
Gridley DS, Gilsson WC, Uhm J-R. Interaction of tumour necrosis factor-α and radiation against human colon tumour cells, 25
Griffin TW *see* Matsushita T
Gubler U *see* Gately MK

Haagen I-A, Geerars AJG, Bast EJEG, de Gast GC, van de Winkel JGJ, de Lau WBM. Evaluation of Fcγ receptor mediated T-cell activation by two purified CD3 × CD19 bispecific monoclonal antibodies with hybrid Fc domains, 279
Hall H, Teuscher C, Urie P, Boden B, Robison R. Induced regression of bovine papillomas by intralesional immunotherapy, 319
Hayden MS, Linsley PS, Gayle MA, Bajorath J, Brady WA, Norris NA, Fell HP, Ledbetter JA, Gilliland LK. Single-chain mono- and bispecific antibody derivatives with novel biological properties and antitumour activity from a COS cell transient expression system, 3
Ho AS-Y, Moore KW. Interleukin-10 and its receptor, 173
Hochman PS *see* Chisholm PL
Howell-Clark J *see* Bilge A
Huh YO *see* Przepiorka D
Hurez V, Kaveri SV, Mouhoub A, Dietrich G, Mani J-C, Klatzmann D, Kazatchkine MD. ANti-CD4 activity of normal human immunoglobulin G for therapeutic use (intravenous immunoglobulin, IVIg), 269

Ikawa Y *see* Sugimoto M
Ildstad ST *see* Kaufman CL
Isaacs JD, Waldmann H. Helplessness as a strategy for avoiding antiglobulin responses to therapeutic monoclonal antibodies, 303

Jacobs C *see* Dower SK
Jones WE *see* Chisholm PL
Juji T *see* Uchida S

Kahan BD. New immunosuppressive drugs – pharmacologic approaches to alter immunoregulation, 33
Kaufman CL, Ildstad ST. Induction of donor-specific tolerance by transplantation of bone marrow, 101
Kaveri SV *see* Hurez V

Kazatchkine MD *see* Hurez V
Kieny M-P *see* Acres B
Killeen N, Littman DR. Lymphocyte development in genetically manipulated mice, 123
Klatzmann D *see* Hurez V
Koffman CG *see* Abbs IC
Kroll RA, Pagel MA, Langone JJ, Sexton GJ, Neuwelt EA. Differential permeability of the blood–tumour barrier in intracerebral tumour-bearing rats: antidrug antibody to achieve systemic drug rescue, 333

Langone JJ *see* Kroll RA
de Lau WBM *see* Haagen I-A
Ledbetter JA *see* Hayden MS
Lee K-M *see* Perrin PJ
LeMaistre CF *see* Przepiorka D
Leung HT, Linsley PS, The CD28 costimulatory pathway, 217
Li WJ *see* Sutton VR
Linsley PS *see* Hayden MS, Leung HT
Lipman JM *see* Gately MK
Littman DR *see* Killeen N
Lloyd IS *see* Greenwood J
Luno M *see* Przepiorka D

Magee JC, Platt JL. Xenograft rejection – molecular mechanisms and therapeutic implications, 45
Majeau GR *see* Chisholm PL
Mani J-C *see* Hurez V
Matsushita T, Griffin TW, Yao Z, Delichatsios H, Brill AB. Human recombinant TNF-α on localization of ^{90}Y-radioantibody in human tumour xenografts, 71
McKenzie IFC *see* Sutton VR
Meier W *see* Chisholm PL
Milesi R *see* Blum S
Miyamoto M *see* Uchida S
Moore KW *see* Ho AS-Y
Mouhoub A *see* Hurez V
Mulligan MS *see* Ward PA

Nadeau RR *see* Gately MK
Naito K *see* Tsuchida M
Neuwelt EA *see* Kroll RA
Newton DL *see* Gadina M
Norris NA *see* Hayden MS
Ohishi K *see* Sugimoto M
Oleson FB *see* Chisholm PL
Olive D *see* Blum S
Oppenheim JJ *see* Taub DD

Pagel MA *see* Kroll RA
Perrin PJ, Fidelus RK, Lee K-M. Phillips SM. The regulation of lymphoid function during schistosomiasis – the influence of T-cell-derived molecules on antigen recognition, cellular activation and granuloma formation, 257
Peterson NC, Greene MI, Considerations in the design and production of small anti-receptor antibody forms: optimizing gains while reducing size, 289
Phillips SM *see* Perrin PJ
Pietersz GA *see* Sutton VR
Platt JL *see* Magee JC
Press OW *see* Bilge A
Przepiorka D, LeMaistre CF, Huh YO, Luno M, Saria EA, Brown CT, Champlin RE. Evaluation of anti-CDS recin a chain immunoconjugate for prevention of acute graft-vs. host disease after HLA-identical marrow transplantation, 77

Ramakrishnan S *see* Bilge A
Robison R *see* Hall H
Routledge EG *see* Greenwood J
Rybak SM *see* Gadina M

Sacks SH *see* Abbs IC
Saria EA *see* Przepiorka D
Sarmiento U *see* Gately MK
Sexton GJ *see* Kroll RA
Sims JE *see* Dower SK
Starzl TE *see* Delaney CP
Stefani L *see* Acres B
Sugimoto M, Ohishi K, Ikawa Y. Role of cell-mediated immunity in bovine leukemia virus (BLV) infection in ruminants: its implication for the vaccination strategy against retroviruses, 297
Sutton VR, Burgess J, Pietersz GA, Li WJ, McKenzie IFC, Trapani JA. The production and preclinical characterization of a chimeric anti-breast-cancer antibody, cBC2, 83
Suzuki K *see* Uchida S

Takai K *see* Tsuchida M
Taub DD, Oppenheim JJ. Chemokines, inflammation and the immune system, 229
Teitelbaum D *see* Arnon R
Teuscher C *see* Hall H
Thomson AW *see* Delaney CP
Trapani JA *see* Sutton VR
Tratkiewicz J *see* Blum S
Tsuchida M, Takai K, Naito K, Fujikura Y, Fukumoto T. The effects of FK506 and dexamethasone on rat thymocyte differentiation, 135

Uchida S, Suzuki K, Akiyama S, Miyamoto M, Juji T, Fujiwara M. Suppressive effect of cyclophosphamide on the progression of lethal graft-versus-host disease in mice – a therapeutic model of fatal post-transfusion GVHD, 313
Uhm J-R *see* Gridley DS
Urie P *see* Hall H

Waldmann H *see* Abbs IC
Waldmann H *see* Greenwood J
Waldmann H *see* Isaacs JD
Ward PA, Mulligan MS, Blocking of adhesion molecules *in vivo* as anti-inflammatory therapy, 165
Waugh S *see* Dower SK
Weber J. The status of HIV/AIDS vaccines – 1993, 95
Widmer MB *see* Dower SK
Williams CA *see* Chisholm PL
van de Winkel JGJ *see* Haagen I-A
Wu Y-N *see* Gadina M

Yao Z *see* Matsushita T
Youle RJ *see* Gadina M

Keyword Index

acute graft-vs.-host disease, 77
adoptive immunotherapy, 143
Ag-MHC-TCR trimolecular complex, 65
allogeneic marrow transplantation, 77
anti-CD4 antibodies, 269
anti-CD5 ricin A chain immunoconjugate, 77
anti-globulin, 303
anti-idiotype, 303
autoimmune diseases, 269

baboons, 205
BC2, 83
bispecific, 3
bispecific hybrid mAb, 279
bispecific monoclonal antibodies, 143
blood–brain barrier, 333
BLV, 297
bone marrow aplasia, 313
bone marrow transplantation, 153
bovine leukeamia virus, 297
brain tumour, 333
breast cancer, 83

cancer therapy, 3, 279
cathepsin, 197
CD2, 205
CD3, 325
CD28 pathway, 143
cell surface antigen, 135
cell-mediated immunity, 297
chemotherapy, 333
chimeric antibody, 83
chimerism, 153
colon adenocarcinoma, 25
complement, 45
complement lysis, 247
complementarity determining region, 289
complications, 303
Corynebacterium parvum, 319
cyclophosphamide, 313
cytokine synthesis inhibitory factor, 173
cytokines, 17, 25
cytokine release, 325
cytoxic T cells, 143

differentiation, 257
domain duplication, 247
drug rescue, 333

endosome, 197
endothelial cell, 45
Epstein–Barr virus, 173
experimental allergic encephalomyelitis, 65

Fab, 289
Fcγ receptor transfectants, 279
FK506, 135
flow cytofluorometry, 135
Fv, 289

gene therapy, 17
glucocorticoid, 135
graft-vs.host disease (GVDH), 313
granuloma, 257

herpesviruses, 173
hyperactive rejection, 45

Ig fusion protein, 205
immunoconjugates, 83
immunohistochemistry, 319
immunology, 257
immunomodulation, 65
immunoregulation, 269
immunosuppression, 153, 205
immunosuppressive agents, 153
immunotherapy, 269, 303, 319
immunotherapy mimetic, 289
immunotoxin, 77, 197
interleukin-10, 173
intravenous immunoglobulins, 269

lethal GVDH, 313
LFA-3, 205
lymphokines, 143
lysosome, 197

methotrexate, 333
monoclonal antibodies, 135, 303, 325, 333
mouse isotopes, 279

natural antibodies, 45
natural autoantibodies, 269
neutrophils, 319

organ transplantation, 153
oxygen radicals, 25

papilloma, 319
pathology, 257
PCR, 83
polymorphic epithelial mucins, 83
post-transfusion GVDH, 313
primates, 205

radiation, 25
rat thymocyte differentiation, 135
recin, 197
recombinant vaccinia virus, 297
regulation, 257

schistosomiasis, 257
sensitization, 303
single-chain antibodies, 3
single-chain Fv, 289
suppressor cells, 65

T-cells, 319
T-cell activation, 143, 279
therapeutic antibodies, 247
therapeutic vaccine, 297
TNF-α, 25
TNF-α xenografts, 71
tolerance, 153
transplantation, 45
transplant rejection, 325
tumour, 17

vaccine, 297
vaccinia virus, 17

xenotransplantation, 45